Last reviewed · How we verify
AeroVanc
Aeruginibactin antibiotic
Aeruginibactin antibiotic Used for Treatment of methicillin-resistant Staphylococcus aureus (MRSA).
At a glance
| Generic name | AeroVanc |
|---|---|
| Sponsor | Savara Inc. |
| Drug class | Siderophore antibiotic |
| Target | Aeruginibactin receptor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 1 |
Mechanism of action
Aeruginibactin is a siderophore antibiotic that targets the Aeruginibactin receptor, inhibiting bacterial growth.
Approved indications
- Treatment of methicillin-resistant Staphylococcus aureus (MRSA)
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis (PHASE3)
- Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients (PHASE2)
- Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AeroVanc CI brief — competitive landscape report
- AeroVanc updates RSS · CI watch RSS
- Savara Inc. portfolio CI